Roivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High Following Analyst Upgrade

Roivant Sciences Ltd. (NASDAQ:ROIV)’s share price reached a new 52-week high during trading on Wednesday after HC Wainwright raised their price target on the stock from $33.00 to $34.00. HC Wainwright currently has a buy rating on the stock. Roivant Sciences traded as high as $29.72 and last traded at $28.93, with a volume of 1839027 shares. The stock had previously closed at $27.85.

Several other research firms have also recently commented on ROIV. The Goldman Sachs Group raised their price target on shares of Roivant Sciences from $24.00 to $33.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Weiss Ratings lowered shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, February 9th. Guggenheim boosted their price target on shares of Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, February 9th. Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. Finally, TD Cowen reissued a “buy” rating on shares of Roivant Sciences in a research report on Saturday, February 7th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Roivant Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $28.81.

Insider Buying and Selling

In other news, insider Frank Torti sold 587,390 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $27.51, for a total value of $16,159,098.90. Following the completion of the sale, the insider directly owned 13,736,547 shares in the company, valued at approximately $377,892,407.97. The trade was a 4.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $26.49, for a total transaction of $5,298,000.00. Following the sale, the chief executive officer directly owned 1,654,597 shares of the company’s stock, valued at approximately $43,830,274.53. This represents a 10.78% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 13,318,014 shares of company stock valued at $315,727,023 in the last quarter. Company insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

A number of hedge funds have recently bought and sold shares of the company. Pacer Advisors Inc. increased its stake in shares of Roivant Sciences by 24.0% in the fourth quarter. Pacer Advisors Inc. now owns 70,259 shares of the company’s stock worth $1,525,000 after purchasing an additional 13,609 shares during the period. Dorsey Wright & Associates bought a new stake in Roivant Sciences during the 4th quarter valued at approximately $8,162,000. Invesco Ltd. grew its holdings in Roivant Sciences by 28.9% in the 4th quarter. Invesco Ltd. now owns 2,281,487 shares of the company’s stock valued at $49,508,000 after buying an additional 512,129 shares during the last quarter. Mercer Global Advisors Inc. ADV bought a new position in Roivant Sciences in the 4th quarter worth approximately $227,000. Finally, Empowered Funds LLC bought a new position in Roivant Sciences in the 4th quarter worth approximately $396,000. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Price Performance

The company has a market capitalization of $21.27 billion, a price-to-earnings ratio of -25.40 and a beta of 1.17. The business has a fifty day moving average price of $24.43 and a 200 day moving average price of $19.92.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.